Subject Index

Editorials, Letters to the Editor, Case Reports and Short Reports are indicated by (E), (L), (CR) and (SR) after the page numbers, respectively.

A&E data retrieval 61–66
ACE levels
  in metastatic ovarian dysgerminoma 237–9 (CR)
  non-correlation with radiographic staging of sarcoidosis 399–401
N-acetylcysteine as antioxidant enhancer 159–68
adenocarcinoma *see under* pulmonary
adenoid cystic carcinoma metastasis manifested by pleural effusion 169–70 (CR)
airway
  challenge test, lung auscultation in 151–7
  inflammation following ozone exposures 47–55
  inflammatory changes in asthmatic patients 323–6
  obstructive syndrome, inflammatory pseudotumour of lung presenting as 381–4 (CR)
  stenosis after tracheo-bronchial tuberculosis 107–10 (CR)
alveolar
  haemorrhage revealing epitheloid haemangioendothelioma 111–14 (CR)
  pneumonia, KL–6, type III procollagen N-terminal peptide and type IV collagen 7S in 558- 61
  volume effect on single breath D_LCO interpretation 263–73
aminophylline effects on spirometry and exercise tolerance in COPD 327–34
anaesthesia in ICU, propofol for 505–10
angiotensin II effect on bronchoconstriction 609–15
antibiotic use in acute lower RTI in general practice in UK 427–34
antioxidant enhancement by nacystelyn and N-acetylcysteine 159–68
α_1-antitrypsin deficiency
  BMI and mortality in subjects with 77–82
  diagnostic value in pleural effusion differentiation 517–23
  -induced emphysema, glucocorticosteroid inhalation effect 275–9
asbestos exposure causing pleural mesothelioma and pulmonary adenocarcinoma, use of MOC_{31} to distinguish 57–60 (CR)
aspergillosis
  allergic bronchopulmonary, CT scans 213–19
  cerebromeningeal involvement after i.v. corticosteroid therapy in asthma 435–7 (CR)
asthma
  β_2-agonists use 587–91
  brittle, low IgG subclass levels in 464–9
  care in GP 578–80
  cerebromeningeal involvement in aspergillosis after i.v. corticosteroid therapy 435–7 (CR)
  education intervention, attendance 524–9
  effect of inspiratory capacity on bronchodilatation via Turbohaler® or pressurized metered-dose inhaler 341–6
  guidelines in GP 575–7 (E)
  hospitalization in island population 411–16
  inflammatory changes in airways 323–6
  monitoring, bronchial 581–6
  morbidity reduction in community, asthma clinic and 634–40
  pathogenesis A1-A46
  prevalence in Athens 83–88
  social deprivation and 603–8
  statistics in Netherlands 1980–84 417–22
  steroid hypersensitivity 231–3 (SR)
  suspected, value of cold air hyperventilation in 470–8
  symptom deterioration from isoniazid prophylaxis 438–40 (CR)
  related attendances data in A&E, retrieval method 61–66
  self-reported, prevalence in Ankara 461–3
  symptomatic 121–34
atrial tumour, left, mimicking pulmonary embolism 562–3 (CR)

basement membrane thickness in bronchial epithelial cells in lung disease 406–10
β_2-agonists use 587–91
blood lymphocyte cell subsets in COPD associated with smoking, IgE and lung function 67–76
body mass index and mortality in subjects with severe α_1-antitrypsin deficiency 77–82
Book Reviews
  Airway smooth muscle: modelling the asthmatic response in vivo 179
  Prehospital emergency care: a guide to paramedics 3rd edn 441
breast cancer radiotherapy, bronchiolitis obliterans organizing pneumonia following 241- 4 (CR)
bronchial
  epithelial cells in lung disease, thickness of basement membrane 406–10
  hyper-responsiveness loss following ozone exposures 47–55
  hyper-responsiveness, symptomatic 121–34
  tone, lack of inhibition by nitric oxide 335–40
bronchiectasis in Finland, hospital treatment 395–8
bronchiolitis obliterans
  in HIV infection 171–3 (CR)
  organizing pneumonia after radiotherapy for breast cancer 241–4 (CR)
  steroid-resistant, cyclophosphamide in 175–7 (CR)
bronchitis, chronic, symptoms related to snoring and sleep apnoea 5–12
bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia, interleukin–8 and leukotriene B_4 in 317–21
bronchoconstriction
  angiotensin II effect 609–15
  methacholine-induced, lack of inhibition by nitric oxide 335–40
bronchodilatation via Turbohaler® or pressurized metered-dose inhaler, effect of inspiratory capacity in asthma 341–6

Subject Index

Editorials, Letters to the Editor, Case Reports and Short Reports are indicated by (E), (L), (CR) and (SR) after the page numbers, respectively.

A&E data retrieval 61–66
ACE levels
  in metastatic ovarian dysgerminoma 237–9 (CR)
  non-correlation with radiographic staging of sarcoidosis 399–401
N-acetylcysteine as antioxidant enhancer 159–68
adenocarcinoma *see under* pulmonary
adenoid cystic carcinoma metastasis manifested by pleural effusion 169–70 (CR)
airway
  challenge test, lung auscultation in 151–7
  inflammation following ozone exposures 47–55
  inflammatory changes in asthmatic patients 323–6
  obstructive syndrome, inflammatory pseudotumour of lung presenting as 381–4 (CR)
  stenosis after tracheo-bronchial tuberculosis 107–10 (CR)
alveolar
  haemorrhage revealing epitheloid haemangioendothelioma 111–14 (CR)
  pneumonia, KL–6, type III procollagen N-terminal peptide and type IV collagen 7S in 558- 61
  volume effect on single breath D_LCO interpretation 263–73
aminophylline effects on spirometry and exercise tolerance in COPD 327–34
anaesthesia in ICU, propofol for 505–10
angiotensin II effect on bronchoconstriction 609–15
antibiotic use in acute lower RTI in general practice in UK 427–34
antioxidant enhancement by nacystelyn and N-acetylcysteine 159–68
α_1-antitrypsin deficiency
  BMI and mortality in subjects with 77–82
  diagnostic value in pleural effusion differentiation 517–23
  -induced emphysema, glucocorticosteroid inhalation effect 275–9
asbestos exposure causing pleural mesothelioma and pulmonary adenocarcinoma, use of MOC_{31} to distinguish 57–60 (CR)
aspergillosis
  allergic bronchopulmonary, CT scans 213–19
  cerebromeningeal involvement after i.v. corticosteroid therapy in asthma 435–7 (CR)
asthma
  β_2-agonists use 587–91
  brittle, low IgG subclass levels in 464–9
  care in GP 578–80
  cerebromeningeal involvement in aspergillosis after i.v. corticosteroid therapy 435–7 (CR)
  education intervention, attendance 524–9
  effect of inspiratory capacity on bronchodilatation via Turbohaler® or pressurized metered-dose inhaler 341–6
  guidelines in GP 575–7 (E)
  hospitalization in island population 411–16
  inflammatory changes in airways 323–6
  monitoring, bronchial 581–6
  morbidity reduction in community, asthma clinic and 634–40
  pathogenesis A1-A46
  prevalence in Athens 83–88
  social deprivation and 603–8
  statistics in Netherlands 1980–84 417–22
  steroid hypersensitivity 231–3 (SR)
  suspected, value of cold air hyperventilation in 470–8
  symptom deterioration from isoniazid prophylaxis 438–40 (CR)
  related attendances data in A&E, retrieval method 61–66
  self-reported, prevalence in Ankara 461–3
  symptomatic 121–34
atrial tumour, left, mimicking pulmonary embolism 562–3 (CR)

basement membrane thickness in bronchial epithelial cells in lung disease 406–10
β_2-agonists use 587–91
blood lymphocyte cell subsets in COPD associated with smoking, IgE and lung function 67–76
body mass index and mortality in subjects with severe α_1-antitrypsin deficiency 77–82
Book Reviews
  Airway smooth muscle: modelling the asthmatic response in vivo 179
  Prehospital emergency care: a guide to paramedics 3rd edn 441
breast cancer radiotherapy, bronchiolitis obliterans organizing pneumonia following 241- 4 (CR)
bronchial
  epithelial cells in lung disease, thickness of basement membrane 406–10
  hyper-responsiveness loss following ozone exposures 47–55
  hyper-responsiveness, symptomatic 121–34
  tone, lack of inhibition by nitric oxide 335–40
bronchiectasis in Finland, hospital treatment 395–8
bronchiolitis obliterans
  in HIV infection 171–3 (CR)
  organizing pneumonia after radiotherapy for breast cancer 241–4 (CR)
  steroid-resistant, cyclophosphamide in 175–7 (CR)
bronchitis, chronic, symptoms related to snoring and sleep apnoea 5–12
bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia, interleukin–8 and leukotriene B_4 in 317–21
bronchoconstriction
  angiotensin II effect 609–15
  methacholine-induced, lack of inhibition by nitric oxide 335–40
bronchodilatation via Turbohaler® or pressurized metered-dose inhaler, effect of inspiratory capacity in asthma 341–6

bronchogenic carcinoma, comparison of cytokeratin fragment 19, tissue polypeptide antigen and carcinoembryonic antigen as markers 135–42
bronchopulmonary aspergillosis, allergic, CT scans 213–19
bronchoscopic technique for diagnosis of bacterial pneumonia in HIV-positive patients 530–6
bronchoscopy, rapidly expanding tuberculous lung cavity following 377–9 (CR)
Burkholderia (Pseudomonas) cepacia isolates genetic relatedness from cystic fibrosis centers 485–92

carbon monoxide diffusing capacity in whole lung, single-breath, effect of alveolar volume 263–73
carcinoembryonic antigen as tumour marker in bronchogenic carcinoma 135–42
cerebromeningeal involvement in aspergillosis after i.v. corticosteroid therapy in asthma 435–7 (CR)
chest X-ray results in pulmonary TB diagnosis in low-incidence country 281–5
chronic obstructive pulmonary disease
  effects of ipratropium bromide and aminophylline on spirometry and exercise tolerance 327–34
  hypoxic, adequacy of oxygenation in long-term domiciliary oxygen therapy 287–91,442
  ventilatory response to positive and negative work in 143–9
chylothorax in liver cirrhosis 118–19 (L)
cirrhosis *see under* liver
coal miners, single-breath nitrogen test 479–84
coal-dust exposure, lactate dehydrogenase and isoenzyme pattern in ex-coalminers 616–23
collagen 7S, type IV, in interstitial pneumonitis and alveolar pneumonia 558–61
complement
  consumption in post-traumatic pleural effusion 373–5 (CR)
  factors C3 and C4 diagnostic value in pleural effusion differentiation 517–23
coronary artery bypass surgery, pulmonary function following 629–33
corticosteroid
  comparisons in chronic sarcoidosis 449–60
  inhalation use for asthma in island population 411–16
  therapy in asthma, cerebromeningeal involvement in aspergillosis after 435–7 (CR)
cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia 175–7 (CR)
cystic fibrosis
  centers, *Burkholderia (Pseudomonas) cepacia* isolates genetic relatedness 485–92
  relationship between dyspnoea, pulmonary function and exercise capacity 41–46
cytokeratin fragment 19 as tumour marker in bronchogenic carcinoma 135–42

data retrieval on A&E data 61–66
deflazacort vs prednisone in chronic sarcoidosis 449–60
diffuse interstitial lung disease, alveolar volume effect on single breath DLCO interpretation 263–73
dyspnoea relationship with pulmonary function and exercise capacity in cystic fibrosis 41–46

emphysema
  alveolar volume effect on single breath DLCO interpretation 263–73
  from α_1-antitrypsin deficiency, glucocorticosteroid inhalation effect 275–9
endobronchial metastasis from rectal adenocarcinoma 245–8 (CR)
eosinophilic cationic protein, seasonal variation in general population 347–9
exercise
  capacity relationship with dyspnoea and pulmonary function in cystic fibrosis 41–46
  tests, ventilatory response in COPD 143–9
  tolerance, effects of ipratropium bromide and aminophylline in COPD 327–34

ferritin diagnostic value in pleural effusion differentiation 517–23
Filgrastim safety trial in severe community acquired pneumonia 387–94
forced expiratory flow reduction in children with respiratory symptoms 443–8
foreign body inhalation, overlooked 293–6

gemcitabine clinical trial in advanced non-small cell lung cancer 423–6
glucocorticosteroid inhalation effect in emphysema from α_1-antitrypsin deficiency 275–9

haemangioendothelioma, epitheloid, alveolar haemorrhage revealing 111–14 (CR)
halothane
  administration during liquid ventilation 255–62
  causing pulmonary microvascular injury 351–60
haptoglobin diagnostic value in pleural effusion differentiation 517–23
hard metal lung disease and pneumothorax 103–5 (CR)
head injury, pneumonia and 193–9
hepatocyte growth factor in idiopathic pulmonary fibrosis 511–16
histamine-induced bronchoconstriction, angiotensin II effect 609–15
HIV infection
  bronchiolitis obliterans in 171–3 (CR)
  bronchoscopic technique for diagnosis of bacterial pneumonia in 530–6
  interleukin-8 and leukotriene B_4 in BAL fluid from HIV-infected patients with bacterial pneumonia 317–21
  smoking and clinical status effects on lung function 221–9
human alveolar macrophages, thalidomide effect on TNF-α production by 31–39
hyperhidrosis, essential, partial sympathetic denervation by thoracoscopic D2-D3 sympathociolysis, effect on pulmonary diffusion capacity 537–45
hyperventilation, cold air, value in suspected asthma 470–8

IgE, blood lymphocyte cell subsets in COPD associated with 67–76
IgG subclass low levels in brittle asthma 464–9
immunodeficiency in non-tuberculous mycobacterial disease 95–101
immunotherapy for TB control 1–4(E), 13–19
inflammatory pseudotumour of lung, presenting as airway obstructive syndrome 381–4 (CR)
inhalers
  metered-dose bronchodilatation, effect of inspiratory capacity in asthma 341–6
  Spacehaler™ evaluation for salbutamol delivery 311–16

inspiratory
capacity in asthma, effect on bronchodilatation via Turbohaler® or pressurized metered-dose inhaler 341–6
flow effects on Turbuhaler aerosol particle size distribution 624–8
intensive care unit, sedation with propofol 505–10
interleukin–8 in BAL fluid from HIV-infected patients with bacterial pneumonia 317–21
interstitial pneumonitis, KL–6, type III procollagen N-terminal peptide and type IV collagen 7S in 558–61
intubation, tracheobronchopathia osteochondroplastica presenting at 496–8 (CR)
ipratropium bromide effects on spirometry and exercise tolerance in COPD 327–34
isoflurane causing pulmonary microvascular injury 351–60
isoniazid prophylaxis causing deterioration in asthma symptoms 438–40 (CR)

Kikuchi's disease and SLE 117–18 (L)
KL–6 levels in interstitial pneumonitis and alveolar pneumonia 558–61

lactate dehydrogenase
diagnostic value in pleural effusion differentiation 517–23
and isoenzyme pattern in ex-coalminers 616–23
large cell lung cancer presenting with numb chin syndrome 235–6 (CR)
leukaemia, chronic lymphocytic, chemotherapy-induced myocardial necrosis 564–6 (CR)
leukotriene B_4 in BAL fluid from HIV-infected patients with bacterial pneumonia 317–21
liquid ventilation, halothane administration during 255–62
liver cirrhosis, chylothorax in 118–19 (L)
lung
aspirates, diagnoses of pneumococcal antigen by PCR vs culture 201–6
auscultation in airway challenge test 151–7
cancer, large cell, presenting with numb chin syndrome 235–6 (CR)
non-small cell, gemcitabine clinical trial 423–6
non-small cell, response to chemotherapy analysed by three tumour markers 361–7
cavity expansion, tuberculous, following bronchoscopy 377–9 (CR)
disease from hard metal 103–5 (CR)
mild-moderate, 'Quality-of-Life for Respiratory Illness Questionnaire 297–309
thalidomide effect on tumour necrosis-*a* production 31–39
thickness of basement membrane in bronchial epithelial cells 406–10
function, blood lymphocyte cell subsets in COPD associated with 67–76
function, effects of smoking and clinical status in HIV infection 221–9
inflammatory pseudotumour presenting as airway obstructive syndrome 381–4 (CR)

mechanical ventilation, tracheal strictures following 503–4 (CR)
mesothelioma *see under* pleural 57–60 (CR)
methacholine-induced bronchoconstriction, lack of inhibition by nitric oxide 335–40
MOC_{31} in asbestos sprayer too distinguish between pleural mesothelioma and pulmonary adenocarcinoma 57–60 (CR)
mortality related to BMI in subjects with severe a_1-antitrypsin deficiency 77–82
muscle energy metabolism impairment in sleep apnoea syndrome 551–7
mycobacterial disease, non-tuberculous, immunodeficiency in 95101
Mycobacterium tuberculosis culture results in low-incidence TB country 281–5
Mycobacterium vaccae immunotherapy for tuberculosis 13–19
myocardial necrosis, chemotherapy-induced in chronic lymphocytic leukaemia 564–6 (CR)

nacystelyn as antioxidant enhancer 159–68
neutrophil elastase in idiopathic pulmonary fibrosis 511–16
nitric oxide lack of inhibition on bronchial tone and methacholine-induced bronchoconstriction 335–40
nitrogen test, single-breath, in coal miners 479–84
non-Hodgkin's lymphoma presenting as Pancoast's syndrome 570–1 (CR)
numb chin syndrome in metastatic large cell lung cancer 235–6 (CR)
nurse-run asthma clinic effect on asthma morbidity in community 634–40
nutritional support in advanced pulmonary disease 249–54

obstructive sleep apnoea
in chronic bronchitis, symptoms related to 5–12
diagnosis and treatment 181–91,442
muscle energy metabolism impairment in 551–7
ovarian dysgerminoma, metastatic, ACE levels in 237–9 (CR)
oxygen therapy
importance of process variables in long-term assessment 89–93
long-term, quality of life for patients 592–602
oxygenation adequacy in patients with hypoxic COPD treated with long-term domiciliary oxygen 287–91,442
ozone exposures, airway inflammation following 47–55

Pancoast's syndrome, non-Hodgkin's lymphoma presenting as 570–1 (CR)
PCR for diagnosis of pneumococcal antigen in lung aspirates 201–6
perfluorochemical liquid ventilation, halothane administration during 255–62
pleural
effusion as sign of salivary adenoid cystic carcinoma metastasis 169–70 (CR)
diagnostic criteria 517–23
post-traumatic, local complement consumption 373–5 (CR)
mesothelioma distinguished from pulmonary adenocarcinoma using MOC_{31} in asbestos sprayer 57–60 (CR)
primary biphasic synovial sarcoma 567–9 (CR)
pneumococcal antigen detection in lung aspirates by PCR technique vs culture 201–6
pneumonia
aetiology following isolated closed head injury 193–9
bacterial, bronchoscopic technique for diagnosis in HIV-positive patients 530–6
interleukin–8 and leukotriene B_4 in BAL fluid from HIV-infected patients with 317–21

KL–6, type III procollagen N-terminal peptide and type IV collagen 7S in 558–61
severe community acquired, Filgrastim safety trial in 387–94
see also specific types e.g. varicella pneumonia
pneumothorax from hard metal lung disease 103–5 (CR)
prednisone vs deflazacort in chronic sarcoidosis 449–60
procollagen N-terminal peptide, type III, in interstitial pneumonitis and alveolar pneumonia 558–61
propofol for sedation in ICU 505–10
pulmonary
adenocarcinoma distinguished from pleural mesothelioma using MOC_{31} in asbestos sprayer
aspergillosis with cerebromeningeal involvement after i.v. corticosteroid therapy in asthma 435–7 (CR)
disease, advanced, nutritional support 249–54
TB immunotherapy 13–29
fibrosis, idiopathic, hepatocyte growth factor and neutrophil elastase in 511–16
function after coronary artery bypass surgery 629–33
relationship with dyspnoea and exercise capacity in cystic fibrosis 41–46
microvascular injury following halothane and isoflurane 351–60
nodules in pyoderma gangrenosum 493–5 (CR)
pyoderma gangrenosum, pulmonary nodules in 493–5 (CR)

quality of life in patients on long-term oxygen therapy 592–602
Quality-of-Life for Respiratory Illness Questionnaire 297–309

rectal adenocarcinoma, endobronchial metastasis from 245–8 (CR)
respiratory
infection, asthma exacerbation in, low IgG subclass levels in 464–9
symptoms, self-reported, prevalence in Ankara 461–3
tract infection, lower, current antibiotic use in general practice in UK 427–33

salbutamol delivery, comparisons of inhalers 311–15
salivary adenoid cystic carcinoma metastasis manifested by pleural effusion 169–70 (CR)
sarcoidosis,
ACE levels non-correlation with radiographic staging of 399–401
chronic, corticosteroid comparisons in 449–60
sarcoma, primary biphasic synovial, of pleura 567–9 (CR)
seasonal variation in serum eosinophilic cationic protein in general population 347–9
serum eosinophilic cationic protein, seasonal variation in general population 347–9
single breath DLCO interpretation, alveolar volume effect 263–73
sleep apnoea *see* obstructive sleep apnoea
smoking
blood lymphocyte cell subsets in COPD associated with 67–76
effects on lung function in HIV infection 221–9
snoring in chronic bronchitis, symptoms related to 5–12
social deprivation and asthma 603–8
Spacehaler™ evaluation for salbutamol delivery 311–16
spirometer, pocket-sized turbine, use in children 369–72 (TN)
spirometry, effects of ipratropium bromide and aminophylline in COPD 327–34
steroid hypersensitivity in asthma 231–3 (SR)
sympathociolysis, thoracoscopic, for essential hyperhidrosis 537–45
systemic lupus erythematosus, Kikuchi's disease and 117–18 (L)

thalidomide effect on TNF-α production by human alveolar macrophages 31–39
thoracoscopic sympathicolysis for essential hyperhidrosis 537–45
tissue polypeptide antigen as tumour marker in bronchogenic carcinoma 135–42
tracheal strictures following mechanical ventilation 503–4 (CR)
tracheobronchial tuberculosis, airway stenosis after 107–10 (CR)
tracheobronchopathia osteochondroplastica 499–502 (CR)
presenting at difficult intubation 496–8
tuberculosis
in health service employees in N. Ireland 546–50
immunotherapy 1–4 (E), 13–19
pulmonary, diagnostic strategy 281–5
tracheobronchial, airway stenosis after 107–10 (CR)
tuberculous lung cavity expansion after bronchoscopy 377–9 (CR)
tumor necrosis factor-a production by human alveolar macrophages, thalidomide effect 31–39
tumour marker analysis of response chemotherapy in non-small lung cancer 361–7
Turbohaler® bronchodilatation effect of inspiratory capacity in asthma 341–6
Turbuhaler aerosol particle size distribution, inspiratory flow effects 624–8

varicella pneumonia management 207–13
ventilation, liquid, halothane administration during 255–62
ventilatory response to positive and negative work in patients with COPD 143–9
Volumatic™ evaluation for salbutamol delivery 311–16

wheezing, self-reported, prevalence in Ankara 461–3

Author Index

Aalderen WMC van *see* De Jong W
Abba AA. Kikuchi's disease and SLE 117–18 (L)
Abdulwadud O, Abramson M, Forbes A, James A, Light L, Thien F, Walters EH. Attendance at an asthma educational intervention: characteristics of participants and non-participants 524–9
Abe M *see* Kohno N
Aboussouan LS, Golish JA, Dinner DS, Strome M, Mendelson WB. Limitations and promise in the diagnosis and treatment of obstructive sleep apnoea 181–91,442
Abramson M *see* Abdulwadud O
Adalioğli G *see* Saraçlar Y
Agusti AGN *see* Sauleda J
Akcabay M *see* Gunaydin B
Al-Haijaj MS *see* Al-Majed SA
Al-Kattan K *see* Al-Majed SA
Al-Majed SA, Ashour M, Al-Mobeireek AF, Al-Haijaj MS, Alzeer AH, Al-Kattan K. Overlooked inhaled foreign bodies: late sequelae and the likelihood of recovery 293- 6
Al-Mobeireek AF *see* Al-Majed SA
Alexandrakis M, Coulocheri S, Kyriakou D, Bouros D, Xirouhaki N, Siafakas N, Castanas E, Eliopoulos GD. Diagnostic value of ferritin, haptoglobin, α_1-antitrypsin, lactate dehydrogeanse and complement factors C3 and C4 in pleural effusion differentiation 517–23
Alzeer AH *see* Al-Majed SA
Ameglio F *see* Paone G
Andresen J *see* deBoisblanc BP
App EM *see* Gillissen A
Aquilini M *see* Mariotta S
Arcasoy SM, Bajwa MK, Jett JR. Non-Hodgkin's lymphoma presenting as Pancoast's syndrome 570–1
Arnold AG *see* Wahbi ZK
Ashour M *see* Al-Majed SA
Atkin A *see* Dickinson J
Austin EJ *see* Premaratne UN
Avarlis P *see* Papageorgiou N
Aykut-Baturalip A *see* De Blay F
Ayres JG, Thompson RA. Low IgG subclass levels in brittle asthma and in patients with exacerbations of asthma associated with respiratory infection 464–9

Babacan A *see* Gunaydin B
Badier M *see* Vanuxem D
Bajwa MK *see* Arcasoy SM
Balzan MV *see* Cacciottolo JM
Barbieri V *see* Calderazzo M
Baron J *see* McCabe RN
Bear MB *see* deBoisblanc BP
Belt-Gritter B van der *see* De Jong JW
Benfield TL *see* Krarup E
Berton C *see* Monlun E
Bhagat R *see* Panchal N
Bird AG *see* Froebel KS
Bisetti A *see* Mariotta S
see Paone G
Bjermer L, Larsson L. Long-acting β_2-agonists: how are they used in an optimal wawy? 587–91
Björsson E *see* Janson C
Bohadana A *see* Purohit A
Böllart FGE *see* Froebel KS
Boner AL *see* Dahl R
Bonora S *see* Cazzadore A
Borràs JM *see* Granados A
Bourgkard E, Teculsecu D, Caillier I, Marchand M, Costantino E, Pham QT. The single- breath nitrogen test in coal miners: factors associated with failure to perform 479–84
Bourke SJ *see* Purcell IF
Bouros D *see* Alexandrakis M
Bovyn G *see* Coëtmeur D
Bredin CP *see* Cotter TP
Briens E, Caulet-Maugendre S, Desrues B, Quinquenel Ml, Lena H, Turlin B, Delaval Ph. Alveolar haemorrhage revealing epitheloid haemangioendothelioma 111–14 (CR)
Britton MG *see* Seal EC
Broholm H *see* Meyer CN
Buhagiar A *see* Cacciottolo JM
Burney PG *see* Premaratne UN
Burr ML, Verrall C, Kaur B. Social deprivation and asthma 603–8

Cacciottolo JM, Balzan MV, Buhagiar A. Hospitalization of adults for asthma and inhaled corticsteroid use in an island population 411–16
Caillier I *see* Bourgkard E
Calderazzo M, Gallilli A, Barbieri V, Roccia F, Pelaia G, Tranfa CME, Cavaliere S, Zorzi F. Inflammatory pseudotumour of the lung presenting as an airway obstructive syndrome 381–4 (CR)
Cantin AM *see* Gillissen A
Carlsson C *see* Kimless-Garber DR
Cash ME *see* Shivaram U
Castanas E *see* Alexandrakis M
Caulet-Maugendre S *see* Briens E
Cavaliere S *see* Calderazzo M
Cazzadore A, Di Perri G, Vento S, Bonora S, Fendt D, Rossi M, Lanzafame M, Mirandola F, Concia E. Aetiology of pneumonia following isolated closed head injury 193–9
Çetinkaya F *see* Saraçlar Y
Chong I-W *see* Huang M-S
Clayton RA *see* Ramsay SG
Cobben NAM, Drent M, Schols AMWJ, Lamers RJS, Wouters EFM, Van Diejen-Visser MP. Serum lactate dehydrogenase and its isoenzyme pattern in ex-coal miners 616- 23
Coëtmeur D, Bovyn G, Leroux P, Niel-Duriez M. Tracheobronchopathia osteochondroplastica presenting at the time of a difficult intubation 496–8 (CR)
Coffiner M *see* Gillissen A
Collazos J *see* Díaz F
Comellas M *see* Torre W
Concia E *see* Cazzadore A
Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with *Mycobacterium vaccae* in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease 13–19; 2. Chronic or relapsed disease 21–29
Costantino E *see* Bourgkard E

Cotter TP, Kealy NP, Duggan PF, Curtain A, Bredin CP. Elevated serum angiotensin converting enzyme levels in metastastic ovarian dysgerminoma 237–9 (CR)
Coulocheri S *see* Alexandrakis M
Crimi E *see* Oddera S
Crocker J *see* Ryan PJ
Crompton GK *see* Gunawardena KA
Cuesta M *see* Torre W
Cukier A *see* Vargas FS
Curtain A *see* Cotter TP

Dagg KD *see* Ramsay SG
Dahl R, Martinati LC, Boner AL. Monitoring of bronchial asthma 581–6
Davies CWH, Wathen CG. Kikuchi's disease and SLE 117–18 (L)
De Angelis G *see* Paone G
De Blay F, Aykut-Baturalip A, Goetz J, Purohit A, Perez-Infante A, Hauptmann G, Pauli G. Post-traumatic pleural effusion: demonstration of local complement consumption 373–5 (CR)
see also Monlun E
deBoisblanc BP, Mason CM, Andresen J, Logan E, Bear MB, Johnson S, Shellito J, Summer WR, Nelson S. Phase 1 safety tiral of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia 387–94
De Jong JW, Belt-Gritter B van der, Koëter GH, Postma DS. Peripheral blood lymphocyte cell subsets in subjects with COPD: association with smoking, IgE and lung function 67–76
De Jong W, van der Schans CP, Mannes GPM, van Aalderen WMC, Grevink RG, Koëter GH. Relationship between dyspnoea, pulmonary function and exercise capacity in patients with cystic fibrosis 41–46
De Marchis L *see* Paone G
Dekhuijzen PNR *see* Rooyackers JM
Delaval Ph *see* Briens E
Delpierre S *see* Vanuxem D
Demirel Y *see* Saraçlar Y
Demoncheaux EAG *see* Maniscalo M
Desrues B *see* Briens E
Devadason SG *see* Everard ML
Di Perri G *see* Cazzadore A
Díaz F, Collazos J, Martinez E, Mayo J. Bronchiolitis obliterans in a patient with HIV infection 171–3 (CR)
Dickinson J, Hutton S, Atkin A, Jones K. Reducing asthma morbidity in the community: the effect of a tergeted nurse-run asthma clinic in an English general practice 634–50
Dietrich S *see* Kumar A
Dilworth P *see* Tavares JL
Dinner DS *see* Aboussouan LS
Dirkman JH *see* Maillé AR
Dirksen A *see* Wilcke JTR
Døssing M *see* Meyer CN
Dousse N *see* Janssens J-P
Drent M *see* Cobben NAM
Duggan PF *see* Cotter TP
Dun J, Fan Chung K. Airway inflammation despite loss of bronchial hyper-responsniveness after multiple ozone exposures 47–55

Eliopoulos GD *see* Alexandrakis M
Enander I *see* Janson C
Escarrabill J *see* Granados A
Everard ML, Devadason SG, Le Souëf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler 624–8

Falfuera M *see* Ruiz-González A
Fan Chung K *see* Dun J
Faraone S *see* Maniscalo M
Faurschou P, Viskum K. Artifical pneumothorax by the Veress cannula: efficacy and safety 402–5
Federam DG, Henry G. Chemotherapy-induced myocardial necrosis in a patient with chronic lymphocytic leukaemia 564–6 (CR)
Fendt D *see* Cazzadore A
Flood-Page P *see* Partridge MR
Folgering HTM *see* Rooyackers JM
Forbes A *see* Abdulwadud O
Foresti V, Villa A, Scolari N. Chylothorax in liver cirrhosis 118–19 (L)
Frances C *see* Frans A
Frans A, Nemery B, Veriter C, Lacquet L, Frances C. Effect of alveolar volume on the interpretation of single breath DLCO 263–73
Frey J *see* Janssens J-P
Froebel KS, Böllart FGE, Jellema J, Bird AG, Greening AP. Immunodeficiency in non-tuberculous mycobacterial disease 95–101
Fujino S *see* Kohno N
Fujita J *see* Hojo S

Gaga M *see* Papageorgiou N
Gallilli A *see* Calderazzo M
Galluccioo G *see* Paone G
Gasser Bv
Gillissen A, Jaworska M, Orth M, Coffiner M, Maes P, App EM, Cantin AM, Schultze-Werninghaus G. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence *in vitro* 159–68
Goetz J *see* De Blay F
Golish JA *see* Aboussouan LS
Gorecki P *see* Jawahar DA
Granados A, Escarrabill J, Borràs JM, Rodríguez-Roisín R. The importance of process variables analysis in the assessment of long-term oxygen therapy by concentrator 89–93
Grange JM. Immunotherapy: a new strategy for tuberculosis control 1–4(E)
Greco S *see* Paone G
Greening AP *see* Froebel KS
Grevink RG *see* De Jong W
Griffin R *see* McCabe RN
Guidi L *see* Mariotta S
Guillot C *see* Vanuxem D
Gunawardena KA, Sohal T, Jones JI, Upchurch FC, Crompton GK. The Spacehaler™ for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus Volumatic™ spacer device 311–16
Gunaydin B, Karadenizil Y, Babacan A, Kaya K, Unlu M, Inanir S, Mahli A, Akcabay M, Yardim S. Pulmonary microvascular injury following general anaesthesia with volatile anaesthetics – halothane and isoflurane: a comparative clinical and experimental study 351–60

Håkanson L *see* Janson C
Halme M, Jekunen A, Tamminen K, Mattson K. Phase II study of weekly gemcitabine in advanced non-small cell lung cancer 423–6

Hammond JM *see* Potgieter PD
Hansen HS *see* Mostgaard G
Hauptmann G *see* De Blay F
Henry G *see* Federam DG
Higenbottam T *see* Maniscalo M
Higgins B *see* Wilkinson SM
Hirasawa Y *see* Kohno N
Hirsch T, Peter-Kern M, Koch R, Leupold W. Influence of inspiratory capacity on bronchodilatation via Turbohaler® or pressurized metered-dose inhaler in asthmatic children: a comparison 341–6
Hiwada K *see* Kohno N
Hojo S, Fujita J, Yoshinouchi T, Yamanouchi H, Kamel T, Yamadori I, Otsuki Y, Udea N, Takahara J. Hepatocyte growth factor and neurophil elsatase in idiopathic pulmonary fibrosis 511–16
Holmes W *see* Macfarlane J
Holscher HC *see* Laar JM van
Honicky R *see* Kumar A
Horrigan MC *see* Seal EC
Huang M-S, Jong S-B, Tsai M-S, Lin M-S, Chong I-W, Lin H-C, Hwang J-J. Comparison of cytokeratin fragment 19 (CYFRA 21–2), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma 135- 42
Hueb W *see* Vargas FS
Huelin E *see* Ruiz-González A
Hutton S *see* Dickinson J
Hwang J-J. *see* Huang M-S
Hyldebrandt N *see* Mostgaard G

Ichinose Y *see* Kasugu I
Imbimbo B *see* Rizzato G
Inanir S *see* Gunaydin B

Jacobson R *see* Kumar A
Jaeger A *see* Monlun E
Jahhah F *see* Vanuxem D
James A *see* Abdulwadud O
Jansen DF, Timens W, Kraan J, Rijken B, Postmas DS. Asymptomatic bronchial hyper-responsiveness and asthma 121–34
Janson C, Björsson E, Enander I, Håkanson L. Seasonal variation in serum eosinophilic cationic protein (S-ECP) in a general popoulation sample 347–9
Janssens J-P, Rochat T, Frey J-G, Dousse N, Pichard C, Tschopp J-M. Health-related quality of life in patients under long-term oxygen therapy: a home-based descriptive study 592–602
Jawahar DA, Vuletin JC, Gorecki P, Persechino F, Macera M, Magazeh P. Primary biphasic synovial sarcoma of the pleura 567–9 (CR)
Jaworska M *see* Gillissen A
Jefery GM *see* Lee YC
Jekunen A *see* Halme M
Jellema J *see* Froebel KS
Jett JR *see* Arcasoy SM
Johnson S *see* deBoisblanc BP
Jones B *see* Tsang KWT
Jones JI *see* Gunawardena KA
Jones K *see* Dickinson J
Jong S-B *see* Huang M-S
Jonsson A-C *see* Larsson L-G
Jönsson E *see* Larsson L-G

Kalayci Ö *see* Saraçlar Y
Kamel T *see* Hojo S
Kaptein AA *see* Maillé AR
Karadenizil Y *see* Gunaydin B
Kasugu I, Yanagisawa N, Takkeo C, Koga M, Kiyokawa H, Yonemaru M, Ichinose Y, Toyama K. Multiple pulmonary nodules in association with pyoderma gangrenosum 493–5 (CR)
Kaur B *see* Burr ML
Kaya K *see* Gunaydin B
Kealy NP *see* Cotter TP
Keistinen T *see* Säynäjäkangas O
Kimless-Garber DR, Wolfson MR, Carlsson C, Shaffer TH. Halothane administration during liquid ventilation 255–62
Kivelä S-L *see* Säynäjäkangas O
Kiyokawa H *see* Kasugu I
Koch R *see* Hirsch T
Koëter GH *see* De Jong W
Koga M *see* Kasugu I
Kohno N, Yorokama A, Hirasawa Y, Kondo K, Fujino S, Abe M, Hiwada K. Comparative studies of circulating KL–6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia 558–61
Kok-Jensen A *see* Wilcke A
Kondo K *see* Kohno N
Koning CJM *see* Maillé AR
Kopferschmitt-Kubler MC *see* Purohit A
Koskela HO, Räsänen SH, Tukiainen HO. The diagnostic value of cold air hyerventilation in adults with suspected asthma 470–8
Kotecha S *see* Tavares JL
Kraan J *see* Jansen DF
Krarup E, Vestbo J, Benfield TL, Lundgren JD. Interleukin–8 and leukotriene B_4 in bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia 317- 21
Krieken JHJM van *see* Laar JM van
Kumar A, Dietrich S, Schneider W, Jacobson R, Pouch Downes F, Robinson-Dunn BE, Honicky R, Smith J, Martin R. Genetic relatedness of *Burkholderia (Pseudomonas) cepacia* isolates from five cystic fibrosis centers in Michigan 485–92
Kyriakou D *see* Alexandrakis M
Kyriakou M *see* Papageorgiou N

Laar JM van, Holscher HC, Krieken JHJM van, Stolk J. Bronchiolitis obliterans organizing pneumonia after adjuvant radiotherapy for breast carcinoma 241–4 (CR)
Lacquet L *see* Frans A
Lamers RJS *see* Cobben NAM
Lanzafame M *see* Cazzadore A
Larsson L *see* Bjermer L
Larsson L-G, Lundbäck B, Jonsson A-C, Lindström M, Jönsson E. Symptoms related to snoring and sleep apnoea in subjects with chronic bronchitis: report from the Obstructive Lung Disease in Northern Sweden Study 5–12
Le Souëf PN *see* Everard ML
Lee YC, Wong CS, Jefery GM. Endobronchial metastasis from rectal adenocarcinoma 245–8 (CR)
Lena H *see* Briens E
Leroux P *see* Coëtmeur D
Leupold W *see* Hirsch T

Levy ML. Organize care in general practice: structure and evaluation 578–80
Lewis SA *see* Macfarlane J
Light L *see* Abdulwadud O
Light RW *see* Vargas FS
Lin H-C *see* Huang M-S
Lin M-S *see* Huang M-S
Linder J *see* Purohit A
Lindström M *see* Larsson L-G
Logan E *see* deBoisblanc BP
Loughrey CM *see* Riley M
Lundbäck B *see* Larsson L-G
Lundgren JD *see* Krarup E

Macavei C *see* Corlan E
Macera M *see* Jawahar DA
Macfarlane J, Lewis SA, Macfarlane R, Holmes W. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: implications for developing management guidelines 427–34
Macfarlane R *see* Macfarlane J
MacNee W *see* Morrison D
Maes P *see* Gillissen A
Magazeh P *see* Jawahar DA
Mahli A *see* Gunaydin B
Mahr L *see* Purohit A
Maillé AR, Koning CJM, Zwinderman AH, Willems LNA, Dirkman JH, Kaptein AA. The development of the 'Quality-of-Life for Respiratory Illness Questionnaire (QQL-RIQ)': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic nonspecific lung disease 297–309
Maimó A *see* Sauleda J
Maniscalco M, Sofia M, Smith A, Demoncheaux EAG, Mormile M, Faraone S, Higenbottam T. Lack of effect of nitric oxide inhibition on bronchial tone and methacholine-induced bronchoconstriction in man 335–40
Mannes GPM *see* De Jong W
Marchand M *see* Bourgkard E
Marica C *see* Corlan E
Marinella MA. Metastatic large cell cancer presenting with numb chin syndrome 235–6 (CR)
Propofol for sedation in the intensive care unit: essentials for the clinician 505–10
Mariotta S, Guidi L, Aquilini M, Tonnarini R, Bisetti A. Airway stenosis after tracheo-bronchial tuberuclosis 107–10 (CR)
Marks GB *see* Premaratne UN
Marossis C *see* Papageorgiou N
Marshall B *see* Tavares JL
Marshall SM *see* Purcell IF
Martin R *see* Kumar A
Martinati LC *see* Dahl R
Martinez E *see* Díaz F
Mason CM *see* deBoisblanc BP
Mateo F *see* Shivaram U
Mattey DL *see* Wilkinson SM
Mattson K *see* Halme M
Mayo J *see* Díaz F
McCabe RN, Baron J, Griffin R, Omogbehin M, Snashall PD, Seed WA. Effects of smoking and clinical status on lung function in human immunodeficiency virus-seropositive subjects 221–9
Mendelson WB *see* Aboussouan LS
Meyer CN, Døssing M, Broholm H. Tracheobronchopathia osteochondroplastica 499- 502 (CR)
Milani S *see* Rizzato G
Mirandola F *see* Cazzadore A
Misirhgil Z *see* Saraçlar Y
Monlun E, De Blay F, Berton C, Gasser B, Jaeger A, Pauli G. Invasive pulmonary aspergillosis with cerebromeningeal involvement after short-term intravenous corticosteroid therapy in a patient with asthma 435–7 (CR)
Mormile M *see* Maniscalo M
Morrison D, Skwarski KM, MacNee W. The adequacy of oxygenation with hypoxic chronic obstructive pulmonary disease treated with long-term domiciliary oxygen 287- 91,442
Mostgaard G, Siersted HC, Hansen HS, Hyldebrandt N, Oxhø H. Reduced forced expiratory flow in schoolchildren with respiratory symptoms: the Odense Schoolchild Study 443–8
Mungall IPF *see* Tsang KWT

Nally JE *see* Ramsay SG
Nelson S *see* deBoisblanc BP
Nemery B *see* Frans A
Newman Taylor AJ *see* Wahbi ZK
Niel-Duriez M *see* Coëtmeur D
Nogués A *see* Ruiz-González A
Noppen MMP, Vincken WG. Partial pulmonary sympathetic denervationo by thoracoscopic D2–D3 sympathicolysis for essential hyerhydrosis: effect on the pulmonary dissusion capacity 537–45

Oates JL *see* Ryan PJ
Oddera S, Silvestri M, Sacco O, Crimi E, Rossi GA. Inflammatory changes in proximal and peripheral airways of asthmatic patients 323–7
Omogbehin M *see* McCabe RN
Orth M *see* Gillissen A
Otsuki Y *see* Hojo S
Owen S *see* Wilkinson SM
Oxhø H *see* Mostgaard G

Panchal N, Bhagat R, Pant C, Shah A. Allergic bronchopulmonary aspergillosis: the spectrum of computed tomography appearances 213–19
Pant C *see* Panchal N
Paone G, De Angelis G, Greco S, Portalone L, De Marchis L, Galluccioo G, Taglienti A, Bisetti A, Ameglio F. Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumour markers elaborated by discriminant analysis 361–7
Papageorgiou N, Gaga M, Marossis C, Reppas Chr, Avarlis P, Kyriakou M, Tsipra S, Zeibecogliou K, Tracopoulos G. Prevalence of asthma and asthma-like symptoms in Athens, Greece 83–86
Parker JM *see* Shorr AF
Partridge MR. The implementation of astham guidelines in general pratice 575–7 (E)
Flood-Page P. Multiple tracheal strictures following mechanical ventilation 503–4
Patterson CC *see* Riley M
Paul KP, Schultz T. Evaluation of a pocket-sized turbine spirometer for clinical use with children 369–72

Pauli G *see* De Blay F
see Monlun E
see Purohit A
Payeras A *see* Sauleda J
Pelaia G *see* Calderazzo M
Perez-Infante A *see* De Blay F
Persechino F *see* Jawahar DA
Peter-Kern M *see* Hirsch T
Pham QT *see* Bourgkard E
Pichard C *see* Janssens J-P
Polosa R, Colombrita R, Prosperini G, Cacciola R. A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis 438–40 (CR)
Pons S *see* Sauleda J
Porcel JM *see* Ruiz-González A
Portalone L *see* Paone G
Postma DS *see* De Jong JW
see Jansen DF
Potgieter PD, Hammond JM. Intensive care management of varicella pneumonia 207–12
Pouch Downes F *see* Kumar A
Premaratne UN, Marks GB, Austin EJ, Burney PG. A reliable method to retrieve Accident and Emergency data stored on a free-text basis 61–66
Purcell IF, Bourke SJ, Marshall SM. Cyclophosphamide in severe steroid-resistance bronchiolitis obliterans organizing pneumonia 175–7
Purohit A, Bohadana A, Kopferschmitt-Kubler MC, Mahr L, Linder J, Pauli G
see also De Blay F

Quinquenel MI *see* Briens E

Ramírez J *see* Sauleda J
Ramsay SG, Clayton RA, Dagg KD, Thomson LJ, Nally JE, Thomson NC. Effect of angiotensin II on histamine-indced bronchoconstriction in the human airway both *in vitro* and *in vivo* 609–15
Räsänen SH *see* Koskela HO
Reppas Chr *see* Papageorgiou N
Riboldi A *see* Rizzato G
Riera M *see* Sauleda J
Rijken B *see* Jansen DF
Riley M, Loughrey CM, Wilkinson P, Patterson CC, Varghese G. Tuberculosis in health service employees in Northern Ireland 546–50
Rizzato G, Riboldi A, Imbimbo B, Torresin A, Milani S. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis 449–60
Robinson-Dunn BE *see* Kumar A
Roccia F *see* Calderazzo M
Rochat T *see* Janssens J-P
Rodríguez-Roisín R *see* Granados A
Rooyackers JM, Dekhuijzen PNR, van Herwaarden CLA, Folgering HTM. Ventilatory response to positive and negative work in patients with chronic obstructive pulmonary disease 143–9
Rossi GA *see* Oddera S
Rossi M *see* Cazzadore A
Rubio-Caballero M *see* Ruiz-González A
Ruiz-González A, Nogués A, Falfuera M, Porcel JM, Huelin E, Rubio-Caballero M. Rapid detection of pneumococcal antigen in lung aspirates: comparison with culture and PCR technique 201–6
Rutter HR *see* Seal EC
Ryan PJ, Oates JL, Crocker J, Stableforth DE. Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asebstos sprayer 57–60 (CR)

Sacco O *see* Oddera S
Saraçlar Y, Çetinkaya F, Tuncer A, Kalayci Ö, Adaliogli G, Sekerel BE, Demirel Y, Misirhgil Z. The prevalence of self-reported asthma and respiratory symptoms in Ankara, Turkey 461–3
Sauleda J, Maimó A, Riera M, Ramírez J, Togores B, Pons S, Payeras A, Agusti AGN. A new bronchoscopic technique for the diagnosis of bacterial pneumonia in HIV-positive patients 530–6
Säynäjäkangas O, Keistinen T, Tuuponen T, Kivelä S-L. Bronchiectasis in Finland: trends in hospital treatment 395–8
Schans CP van der *see* De Jong W
Schneider W *see* Kumar A
Schols AMWJ *see* Cobben NAM
Schultz T *see* Paul KP
Schultze-Werninghaus G *see* Gillissen A
Scolari N *see* Foresti V
Seal EC, Rutter HR, Horrigan MC, Britton MG. Left atrial tumour mimicking pulmonary embolism 562–3 (CR)
Seed WA *see* McCabe RN
Seersholm N. Body mass index and mortality in patients with severe a_1-antitrypsin deficiency 77–82
Sekerel BE *see* Saraçlar Y
Senju S *see* Watanabe K
Shaffer TH *see* Kimless-Garber DR
Shah A *see* Panchal N
Shaw RJ *see* Tavares JL
Shellito J *see* deBoisblanc BP
Shim C *see* Shivaram U
Shivaram U, Cash ME, Mateo F, Shim C. Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD 327–4
Shorr AF, Torrington KG, Parker JM. Serum angiotensin converting enzyme does not correlate with radiographic stage at initial diagnosis of sarcoidosis 399–401
Siafakas N *see* Alexandrakis M
Siersted HC *see* Mostgaard G
Silvestri M *see* Oddera S
Skwarski KM *see* Morrison D
Smith A *see* Maniscalo M
Smith J *see* Kumar A
Snashall PD *see* McCabe RN
Sofia M *see* Maniscalo M
Sohal T *see* Gunawardena KA
Stableforth DE *see* Ryan PJ
Stanford CA *see* Corlan E
Stanford JL *see* Corlan E
Stolk J *see* Laar JM van
Strome M *see* Aboussouan LS
Summer WR *see* deBoisblanc BP

Taglienti A *see* Paone G
Takahara J *see* Hojo S
Takkeo C *see* Kasugu I
Tamminen K *see* Halme M

Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw RJ. Thalidomide reduces tumour necrosis factor-α production by human alveolar macrophages 31–39
Teculsecu D *see* Bourgkard E
Teixeira LR *see* Vargas FS
Terra-Filho M *see* Vargas FS
Thien F *see* Abdulwadud O
Thompson RA *see* Ayres JG
Thomsen C. Nutritional support in advanced pulmonary disease 249–54
Thomson LJ *see* Ramsay SG
Thomson NC *see* Ramsay SG
Timens W *see* Jansen DF
Togores B *see* Sauleda J
Tonnarini R *see* Mariotta S
Torre W, Comellas M, Cuesta M. Massive pleural effusion as isolated manifestation of metastatic spread of salivary adenoid cystic carcinoma 169–70 (CR)
Torresin A *see* Rizzato G
Torrington KG *see* Shorr AF
Toyama K *see* Kasugu I
Toyoshima H *see* Watanabe K
Tracopoulos G *see* Papageorgiou N
Tranfa CME *see* Calderazzo M
Tsai M-S *see* Huang M-S
Tsang KWT, Jones B, Mungall IPF. A case of rapidly expanding tuberculous lung cavity after bronchoscopy 377–9 (CR)
Tschopp J-M *see* Janssens J-P
Tsipra S *see* Papageorgiou N
Tukiainen HO *see* Koskela HO
Tuncer A *see* Saraçlar Y
Turlin B *see* Briens E
Tuuponen T *see* Säynäjäkangas O

Udea N *see* Hojo S
Unlu M *see* Gunaydin B
Upchurch FC *see* Gunawardena KA

Van Diejen-Visser MP *see* Cobben NAM
van Herwaarden CLA *see* Rooyackers JM
Vanuxem D, Badier M, Guillot C, Delpierre S, Jahhah F, Vanuxem P. Impairment of muscle energy metabolism in patients with sleep apnoea syndrome 551–7
Vanuxem P *see* Vanuxem D
Vargas FS, Terra-Filho M, Hueb W, Teixeira LR, Cukier A, Light RW. Pulmonary function after coronary artery bypass surgery 629–33
Varghese G *see* Riley M
Vento S *see* Cazzadore A
Veriter C *see* Frans A
Verrall C *see* Burr ML
Vestbo J *see* Krarup E
Villa A *see* Foresti V
Vincken WG *see* Noppen MMP
Viskum K *see* Faurschou P
Vuletin JC *see* Jawahar DA

Wahbi ZK, Arnold AG, Newman Taylor AJ. Hard metal lung disease and pneumothorax 103–5 (CR)
Walters EH *see* Abdulwadud O
Wangoo A *see* Tavares JL
Watanabe K, Senju S, Toyoshima H, Yoshida M. Thickness of the basement membrane of bronchial epithelial cells in lung diseases as determined by transbronchial biopsy 406–10
Wever AMJ *see* Wever-Hess J
Wever-Hess J, Wever AMJ. Asthma statistics in the Netherlands 1980–94 417–22
Wilcke A, Kok-Jensen A. Diagnostic strategy for pulmonary tuberculosis in a low-incidence country: Results of chest X-ray and sputum cultured for *Mycobacterium tuberculosis* 281–5
Wilcke JTR, Dirksen A. The effect of inhaled glucocorticoids in emphysema due to α_1-antitrypsin deficiency 275–9
Wilkinson P *see* Riley M
Wilkinson SM, Higgins B, Owen S, Mattey DL, Woodcock A. An assessment of steroid hypersensitivity in asthma 231–3 (SR)
Willems LNA *see* Maillé AR
Wolfson MR *see* Kimless-Garber DR
Wong CS *see* Lee YC
Woodcock A *see* Wilkinson SM
Wouters EFM *see* Cobben NAM

Xirouhaki N *see* Alexandrakis M

Yamadori I *see* Hojo S
Yamanouchi H *see* Hojo S
Yanagisawa N *see* Kasugu I
Yardim S *see* Gunaydin B
Yonemaru M *see* Kasugu I
Yorokama A *see* Kohno N
Yoshida M *see* Watanabe K
Yoshinouchi T *see* Hojo S

Zeibecogliou K *see* Papageorgiou N
Zorzi F *see* Calderazzo M
Zwinderman AH *see* Maillé AR 21